6.5.2024 15:05:07 CEST | Thor Medical ASA | Mandatory notification of trade
primary insiders

Reference is made to the stock exchange announcement made by Thor Medical ASA
(the "Company") the Company on 21 April 2024 regarding issuance of shares to
members of the board of directors by exercise of vested RSUs, as well as stock
exchange announcement on 2 May 2024 regarding registration of the share capital
increase.

Board member and primary insider of the Company, John Andersen, received 416,990
shares in connection with the exercise of RSUs. John Andersen has now
transferred all 416,990 shares to Scatec Innovation AS where John Andersen is
the CEO, being a close associate of a primary insider of the Company. Primary
insider notifications pursuant to the market abuse regulation article 19 are
attached.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

 * Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
   brede.ellingseter@thormedical.no 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3085/4426/Download%20announcement
%20as%20PDF.pdf

Thor Medical - John Andersen Scatec Innovations - primary insider notification
MAR.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3085/4425/Thor%20Medical%20-%20Jo
hn%20Andersen%20%20Scatec%20Innovations%20-%20primary%20insider%20notification%2
0MAR.pdf